Open AccessDownregulated miR‐144‐3p contributes to progression of lung adenocarcinoma through elevating the expression of EZH2
Author(s) -
Liu Chao,
Yang Zuozhang,
Deng Zhiyong,
Zhou Youjun,
Gong Quan,
Zhao Ruilian,
Chen Ting
Publication year - 2018
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1714
Subject(s) - mmp2 , gene knockdown , adenocarcinoma , cancer research , ezh2 , biology , western blot , in vivo , cell culture , mtt assay , microbiology and biotechnology , downregulation and upregulation , methylation , cancer , gene , genetics
Objectives The intention of our study was to investigate the relationship between miR‐144‐3p and EZH2 as well as the effects of their interaction on cell propagation and invasiveness in lung adenocarcinoma (LUAD). Methods The expression levels of miR‐144‐3p and EZH2 in LUAD tissues and normal tissues were determined by qRT‐PCR. The dual‐luciferase reporter assay was utilized to validate the targeting relationship between miR‐144‐3p and EZH2 . MTT assay and colony formation assay were performed to evaluate the viability and propagation of LUAD cells, while the effects of miR‐144‐3p and EZH2 on LUAD cell invasiveness were confirmed by transwell assay. Protein expression levels of VEGFA , MMP2, and MMP9 were measured by Western blot. Furthermore, xenograft tumor models were established to verify the effects of miR‐144‐3p on tumor formation and EZH2 , VEGFA , MMP2 and MMP9 expressions in vivo. Results miR‐144‐3P was downregulated in LUAD tissues, and overexpression of miR‐144‐3p inhibited propagation and invasiveness of LUAD cells. EZH2 was a target of miR‐144‐3p and was highly expressed in LUAD cells. Knockdown of EZH2 could suppress the propagation and invasion of LUAD cells. Increased miR‐144‐3p expression exerted an inhibitory effect on LUAD tumor formation in vivo. Conclusion Overexpression of miR‐144‐3p impeded the propagation and invasiveness of LUAD cells by targeting EZH2 .